Imaging system produces human cellular morphological data for COVID-19 research
With the COVID-19 pandemic impacting millions around the globe, researchers are racing to develop a vaccine or drug treatment.
In an effort to better understand the cellular responses to COVID-19, the digital biology company Recursion has publicly released the world’s largest imaging dataset portraying therapeutic compound effects from over 1,600 approved and referenced molecules on SARS-CoV-2-infected human cells. The images and data were acquired using the ImageXpress Micro Confocal High-Content Imaging System from Molecular Devices.
Named RxRx19, the dataset from Recursion is an important contribution to a growing body of scientific data in the fight against COVID-19. The images and datasets are available and free online, giving researchers open access to both the images and the corresponding deep learning embeddings to analyse or apply to their own experimentation hypothesis.
“We commend Recursion for its leadership around RxRx19, empowering researchers with the statistically relevant data to advance our understanding of COVID-19 cellular responses and drug discovery. It is particularly valuable during this unprecedented time when many labs are operating at reduced capacity or are shutdown altogether due to shelter-in-place requirements,” said Susan Murphy, President of Molecular Devices. “This is a powerful example of how our innovative, high-content imaging technology enables customers to provide data to insights quickly and reliably to help explore treatments for COVID-19.”
Oxford University and AstraZeneca partner for COVID-19 vaccine candidate READ MORE
Novasep teams up with AstraZeneca to produce COVID-19 vaccine for Europe READ MORE
Dexamethasone identified as potential for treatment of COVID-19 ten weeks ago READ MORE
Taconic Biosciences to distribute critical COVID-19 mouse model READ MORE
Symbiosis to manufacture COVID-19 vaccine for clinical trials READ MORE
Avacta positive on evaluation of COVID-19 test strips READ MORE
PrecisionLife identifies 68 genes associated with risk of severe COVID-19 READ MORE
MMR vaccination might protect children from COVID-19 READ MORE
EUSA Pharma receives FDA approval of phase III clinical trial for siltuximab READ MORE
Sanofi and Regeneron stop Kevzara COVID-19 trial in US READ MORE